30 93

Cited 0 times in

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy

DC Field Value Language
dc.contributor.author강은석-
dc.contributor.author김영숙-
dc.contributor.author이민영-
dc.contributor.author이병완-
dc.contributor.author차봉수-
dc.date.accessioned2022-08-23T00:38:14Z-
dc.date.available2022-08-23T00:38:14Z-
dc.date.issued2022-06-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/189538-
dc.description.abstractAims: Glucagon-like peptide 1 (GLP-1) receptor agonists have demonstrated strong glycemic control. However, few studies have investigated the effects of switching from insulin to GLP-1 receptor agonists. We aimed to investigate, using real-world data, whether switching to dulaglutide improves glycemic control in patients with type 2 diabetes mellitus (T2D) inadequately controlled with conventional insulin treatment. Materials and methods: We retrospectively evaluated 138 patients with T2D who were switched from insulin to dulaglutide therapy. We excluded 20 patients who dropped out during the follow-up period. The participants were divided into two groups according to whether they resumed insulin treatment at 6 months after switching to a GLP-1 receptor agonist (group I) or not (group II). A multiple logistic regression analysis was performed to evaluate the parameters associated with the risk of resuming insulin after replacement with dulaglutide. Results: Of 118 patients initiated on the GLP-1 receptor agonist, 62 (53%) resumed insulin treatment (group I), and 53 (47%) continued with GLP-1 receptor agonists or switched to oral anti-hypoglycemic agents (group II). Older age, a higher insulin dose, and lower postprandial glucose levels while switching to the GLP-1 receptor agonist were associated with failure to switch to the GLP-1 receptor agonist from insulin. Conclusions: A considerable proportion of patients with T2D inadequately controlled with insulin treatment successfully switched to the GLP-1 receptor agonist. Younger age, a lower dose of insulin, and a higher baseline postprandial glucose level may be significant predictors of successful switching from insulin to GLP-1 receptor agonist therapy.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherFrontiers Research-
dc.relation.isPartOfFRONTIERS IN ENDOCRINOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHBlood Glucose / analysis-
dc.subject.MESHDiabetes Mellitus, Type 2* / drug therapy-
dc.subject.MESHGlucagon-Like Peptide-1 Receptor / agonists-
dc.subject.MESHGlucagon-Like Peptides / analogs & derivatives-
dc.subject.MESHHumans-
dc.subject.MESHImmunoglobulin Fc Fragments-
dc.subject.MESHInsulin*-
dc.subject.MESHRecombinant Fusion Proteins-
dc.subject.MESHRetrospective Studies-
dc.titleTolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYoungsook Kim-
dc.contributor.googleauthorJi Hye Huh-
dc.contributor.googleauthorMinyoung Lee-
dc.contributor.googleauthorEun Seok Kang-
dc.contributor.googleauthorBong-Soo Cha-
dc.contributor.googleauthorByung-Wan Lee-
dc.identifier.doi10.3389/fendo.2022.880164-
dc.contributor.localIdA00068-
dc.contributor.localIdA00715-
dc.contributor.localIdA05491-
dc.contributor.localIdA02796-
dc.contributor.localIdA03996-
dc.relation.journalcodeJ03412-
dc.identifier.eissn1664-2392-
dc.identifier.pmid35784534-
dc.subject.keywordGLP-1 receptor agonist-
dc.subject.keywordinsulin therapy-
dc.subject.keywordswitching to GLP-1 receptor agonist-
dc.subject.keywordtype 2 diabetes-
dc.subject.keywordtype 2 diabetes inadequately controlled with insulin therapy-
dc.contributor.alternativeNameKang, Eun Seok-
dc.contributor.affiliatedAuthor강은석-
dc.contributor.affiliatedAuthor김영숙-
dc.contributor.affiliatedAuthor이민영-
dc.contributor.affiliatedAuthor이병완-
dc.contributor.affiliatedAuthor차봉수-
dc.citation.volume13-
dc.citation.startPage880164-
dc.identifier.bibliographicCitationFRONTIERS IN ENDOCRINOLOGY, Vol.13 : 880164, 2022-06-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.